Information Provided By:
Fly News Breaks for November 15, 2019
Nov 15, 2019 | 06:13 EDT
BofA/Merrill analyst Tazeen Ahmad upgraded BioCryst to Buy from Neutral but lowered his price target to $4, down from $5. The analyst says that he has conducted doctor checks after the release of the ApeX-2 study results in hereditary angioedema earlier this year to determine whether his peak sales estimates for the HAE market for '7353 seemed reasonable. Ahmad notes that while the doctors still gave preference to Takeda's Takhzyro as the best option given its superior efficacy and infrequent dosing, they also expressed interest in '7353 thanks to its oral dosing convenience. Ahmad adds that he has been on the sidelines on BioCryst because of its funding needs, but sees this week's $55M equity raise boosting its cash cushion.
News For BCRX From the Last 2 Days
There are no results for your query BCRX